Bonus BioGroup Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BONS.TA research report →
Price Chart
About the company
Bonus BioGroup Ltd. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions through tissue engineering and cell-based therapies. Their flagship products include BonoFill, which is developed for regenerating bone tissue in maxillofacial and orthopedic applications, and MesenCure, aimed at treating COVID-19 patients suffering from pneumonia and acute respiratory distress syndrome (ARDS), as well as other life-threatening acute inflammatory illnesses.
- CEO
- Shai Meretzki
- IPO
- 2002
- Employees
- 42
- HQ
- Haifa, HA, IL
Get TickerSpark's AI analysis on BONS.TA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $214.90M
- P/E
- -18.04
- PEG
- -0.13
- P/S
- 0.00
- P/B
- -37.94
- EV/EBITDA
- -10.06
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 667.39%
- ROIC
- -734.63%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,756,000+1.3%
- Op Income
- $-22,636,000
- Net Income
- $-24,490,000+12.0%
- EPS
- $-0.04-53.8%
- OCF Growth
- +30.1%
- FCF Growth
- +31.2%
- 52W High
- $60.90
- 52W Low
- $17.70
- 50D MA
- $28.32
- 200D MA
- $35.58
- Beta
- 0.89
- RSI (14)
- 21
- Avg Volume
- 1.32M
No earnings-call transcripts are available for BONS.TA yet.
- Free Float
- 88.5%
- Shares Outstanding
- 1.17B
- Float Shares
- 1.03B
Our BONS.TA coverage
Recent articles, reports, and earnings notes.
No research on BONS.TA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BONS.TA report →